Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15

SIMON FRASER UNIVERSITY

Senate Committee on University Priorities

Memorandum

S.07-53

TO: Senate

FROM:

John WaterhuJ'

Chair, SCUFC'

Vice Presides Academic

RE: Nanomed Canada Research Network

DATE: ?

March 9, 2007

(SCUP 07-23)

At its March 7, 2007 meeting SCUP reviewed and approved the proposal for the

creation of the Nanomed Canada Research Network. This will be a Schedule B Centre

reporting to the Vice President Research, under Policy R40.01.

Motion

That Senate approve and recommend to the Board of Governors the creation of

the Nanomed Canada Research Network (NANOMED Canada) as a Schedule B

Centre reporting to the Vice President Research.

SIMON FRASER UNIVERSITY

MEMORANDUM

OFFICE OF VICE-PRESIDENT, RESEARCH

TO: Sarah Dench, Secretary

FROM: ?

B. Mario Pinto

Senate Committee on University

Vice-President, Research

Planning (SCUP)

RE: Nanomed Canada Research

DATE: ?

March 2, 2007

Network (NANOMED CANADA)

Attached is a proposal from Dr. Neil Branda, Department of Chemistry, for the

establishment of the Nanomed Canada Research Network (NANOMED CANADA) as a

Schedule B Centre.

The Governing Committee for Centres and Institutes recommends that the Centre be

granted approval by SCUP. Once approved by SCUP, the proposal is to be forwarded to

Senate, followed by submission to the Board of Governors.

•

Governing Committee:

/John H. Waterhouse

"-ice-President, Academic and Provost

Dr. B. Mario Pinto

Vice-President, Research

Attachment

C: ?

Dr. Neil Branda, Department of Chemistry

Nanomed Canada Research Network

APPLICATION FOR UNIVERSITY CENTRE STATUS

Health care is a highly visible and growing concern for governments, taxpay-

ers and the general population. With many countries including Canada facing

an increasingly aging society, along with higher costs for medication and hos-

pital care, the need for new solutions is vast. There are signs that we are in the

midst of an explosion of new health-related technologies. ... traditional sci-

ences and technology are undergoing significant changes that could have a

far-reaching impact on all aspects of scientific research, including health. This

change is being brought on by the recent ability to measure, manipulate and

organize matter at the nanoscale, where biology, chemistry, physics, engineer-

ing and material science converge towards the same principals and tools. As a

result, progress in scientific research including health can be greatly acceler-

ated leading to new discoveries never before imagined.

Nanomedicine Taxonomy prepared for the Canadian

Institutes of Health Research, February 2003

I. STATEMENT OF SPECIAL PURPOSE

The Nanomed Canada Research Network (NANOMED CANADA) is a growing commu-

nity of nanotechnology researchers (chemists, physicists, mathematicians and engi-

neers), medical researchers (clinicians, biotech nologists, pharmacologists and geneti-

cists), medical institutes, pharmaceutical and diagnostic companies and government

organizations committed to sharing knowledge and working collaboratively to advance

medical diagnostics and therapeutics. NANOMED CANADA's initial focus will be on

cancer; cardiovascular disease and central nervous system disorders.

Canada has demonstrated research leadership in both the nano and applied side of

this equation; however, the two groups rarely have the opportunity to cross paths and

share knowledge. While all network members see tremendous opportunity for collabo-

ration, their busy schedules make it difficult to find time to move out of their day-to-day

commitments to build new relationships in areas that they might not completely under-

stand - where results can be important, but might take a long time to achieve.

With this in mind, NANOMED CANADA is using the power of the internet to create a

virtual community, where information can be exchanged and accessed anywhere and

anytime. Specific features will include on-going discussions through forum posts,

weekly on-line presentations that will be archived for viewing at any time, a member-

ship directory, a catalogue of relevant research facilities and appropriate contacts

across Canada, private collaborative workrooms and social networking technologies

aimed at facilitating valuable information exchange. NANOMED CANADA will host

quarterly topically-focused meetings aimed at developing collaborative research pro-

jects around topics that will advance nanomedicine. Network members who cannot at-

tend the face-to-face meetings will be able to access relevant presentations and sum-

mary papers through the virtual network.

Once this virtual community is in place and is noted for providing value to the commu-

nity, it is anticipated that the network will grow and stimulate more and more collabora-

tion among academic, government and industry members. NANOMED CANADA will

have a public face with several open-participation events and presentations. These will

be promoted to non-members, with the goal of attracting appropriate new members to

the network.

NANOMED CANADA

Will

become known as a warehouse of information on Canada's

nanomedicine industry. This will enable it to play a matchmaking role between compa-

nies and researchers, which will facilitate technology transfer. It is anticipated that

companies would contact NANOMED CANADA for recommendations on obtaining cer-

tain types of expertise from universities, and university researchers would contact

NANOMED CANADA to get a list of companies that would be interested in a particular

technology that they have patented.

NANOMED CANADA members appreciate that implementing new technologies can

• have a profound effect on public health. A secondary benefit of the network will be its

relevant expertise to help policy makers and regulatory agencies evaluate the scientific

and ethical impact of new nanomedicine technologies.

Specific features of NANOMED CANADA's internet environment will include:

A public face with profiles of the researchers and organizations involved in

NANOMED CANADA, a listing of Canadian research facilities with contact infor-

mation, availability and costs to access each, links to nanomedicine related news

stories automatically updated daily from the wire, upcoming nanomedicine events

and monthly highlights that promote the progress, successes, programs and re-

searchers of NANOMED CANADA. Anyone will be able to subscribe to have these

highlights delivered to their desktop as a newsletter, receiving just the headlines

and lead sentences with links back to the website. The public site will also enable

any person to request membership on-line; however, membership will need to be

approved by NANOMED CANADA management to ensure that the community

maintains a high level of valuable interaction.

• A members-only site aimed at sharing information and collaborating on-line.

NANOMED CANADA has contracted Donat Group Enterprises to apply the com-

pany's technological innovation aimed at leveraging social networks to mine or

filter large aggregations of content. This innovative platform technology was cre-

ated in partnership with SFU and Genome BC. The new technology, originally de-

veloped in Vancouver for the music and e-learning communities with support from

the National Research Council Industrial Research Assistance Program (NRC-

1/.

IRAP), works in the background to weigh the value of incoming information to a

user based on previous interactions with members of a community. The technol-

ogy improves the value of interactions for all members of a large group and helps

to accelerate information sharing. The collaborative site will incorporate features

such as discussion forums, self organized workgroups (closed or open), docu-

ment archiving and the ability to self-post upcoming events, news items, bio-

graphical information and specifications on new facilities.

Regular on-line members-only presentations from graduate students or other re-

searchers initiated from anywhere in Canada or internationally. These presenta-

tions will be conducted through a collaborative voice over internet protocol (V0IP)

and whiteboard application called Marratech, so that interactive dialogue and

idea exchange can begin immediately. Marratech allows viewers to pose ques-

tions by accessing and writing on a whiteboard directly from their own PC, Mac or

Linux workstations. NANOMED CANADA has test driven the Marratech platform.

It was easy to use and had no barriers to entry for participants from industry, uni-

versity or government. Presentations and collaborative discussions will be ar-

chived for later viewing to accommodate researchers' busy schedules. These can

be searched by date, topic, presenter, supervisor or other key words.

While the internet will provide ongoing dialogue and information exchange among

users, it cannot deliver all of NANOMED CANADA's goals without complementary

activities that drive researchers to the website. Face-to-face meetings are neces-

sary to initiate new relationships and explore topics in deeper, more-focused envi-

ronments. NANOMED CANADA will host quarterly research symposia, from differ-

ent locations throughout Canada, around specific issues and research problems.

One topic example might be, "How do we integrate new nanomaterials with living

tissue?" Topics will be selected by NANOM ED CANADA's Management Commit-

tee, which will be comprised of representatives, from industry, university and gov-

ernment. Prior to selecting topics, the Management Committee will seek input

from the larger membership through an internet forum. Then topics will be posted

on NANOMED CANADA's website asking members to supply and review relevant

background material and provide initial thoughts. Partial funding has been se-

cured from the Vancouver Coastal Health Research Institute to support meetings

and workshops for the first 5 years of the Network's program.

II. PROVISION FOR THE APPOINTMENT OF A DIRECTOR

Dr. Neil Branda is the founder and current Director. He will continue as Director and will

report to the university through the appropriate Administrative Director according to the

University Policy Policy (R 40.01) set forward for University Centres and Institutes.

As a 2005 NSERC Steacie Fellowship winner and a Canada Research Chair in Materi-

als Science, Neil Branda has been recognized as one of Canada's leading young scien-

tists. Dr. Branda is currently a Professor of Chemistry at Simon Fraser University and

Director of Molecular Systems at 4D LABS, Simon Fraser University's new $35 million

'5-.

research facility for new materials and nanoscale devices. He also represents Simon

Fraser University as a Steering Committee Member of the BC Nanotechnology Alli-

ance.

III.

IDENTIFICATION OF THE APPLICABLE SCHEDULE

NANOMED CANADA is not intended to replace existing programs, but rather to pro-

vide a mechanism for expanding participation in those that exist and for creating new

ones. The goal of NANOMED CANADA is to be a backbone network that connects a

series of subnetworks across Canada and internationally. Members will act as relay

points on the network, providing relevant info to their own subnetworks and encourag-

ing participation in NANOMED CANADA.

Given the trans-disciplinary scope of the network's interests, Schedule B is the most

appropriate for ongoing activities, with the Network's Administrative Director being

SFU's Vice President of Research.

IV.

STATEMENT THAT RECOGNIZES THE CENTRE'S OBLIGATION TO CONDUCT

ITS ACTIVITIES IN ACCORDANCE WITH THE UNIVERSITY POLICIES

The Nanomed Canada Research Network recognizes its obligation to conduct is activi-

ties in accordance with university policies.

is ?

V. BUDGET IMPLICATIONS / LIBRARY NEEDS

Ongoing funding development is required to secure additional partnerships and provide

financial support for the Network's activities. / One of the goals of the Network is to

build content based on the actions of the users. Library support is, therefore minimal.

VI. STATEMENT OF INTERNAL GOVERNING PROCEDURE

The network will be administered by Simon Fraser University and will take full advan-

tage of the expertise and contacts already developed by SFU's new $35 million re-

search institute for new materials and nanoscale devices - 4D LABS. The following

chart outlines the Management Structure.

Dr. Mario Pinto ?

Administrative Director

VP Research, SFtJ

Dr. Neil Branda

Director

Professor of Chemistry & Canada Research

Chair in Materials Science, SFU

Director, Molecular Systems, 4D LABS, SFU

IBA

DONAT

Network Manager

Systems Administrators

National Scientific Committee

16 members from across Canada

(see members listing)

Network Members

by subscription

The Network Director will report to SFU's Vice President of Research as Administrative

Director. This will ensure that NANOMED CANADA operates within the guidelines of the

University. The Administrative Director will report to the University's Governing Com-

mittee for Centres.

The Network Director will also chair NANOMED CANADA's Network Steering Commit-

tee. It is anticipated that a portion of the Director's time will be dedicated to interna-

tional travel, promoting NANOMED CANADA and building international partnerships.

The remainder of his time will be reserved duties for operational issues and to partici-

pate as a member of the NANOMED CANADA Network Steering Committee.

Network Steering Committee

The NANOMED CANADA Network Steering Committee consists of a sub-group of the

network members with representation from both the researcher and receptor side. It

currently has sixteen members, with a mix of research expertise from fundamental

nanoscience through to medical applications development. Initial members were se-

lected by the Network Director based on their fit into this mix and their willingness and

:1-,

ability to commit to the responsibilities of the Committee. The Network Steering Com-

mittee will provide overall strategic direction, with an emphasis on the following activi-

ties:

selecting topics for face-to-face meetings

setting the criteria for NANOMED CANADA membership

encouraging graduate students and PDFs to deliver weekly on-line presentations

4. recruiting new members from their subnetworks

advising on the effective use of NANOMED CANADA resources

providing feedback on the quality of NANOMED CANADA activities

annually reviewing the NANOMED CANADA vision and performance and making

recommendations for change or improvement

This multidisciplinary group includes expertise in a wide range of areas that NANOMED

CANADA requires to advance interesting collaborative projects. And, since each re-

searcher has built industry-university-governnent networks of their own, in Canada

and internationally, NANOMED CANADA has a strong and diverse base for rapid

growth in membership. It will soon include all of knowledge and expertise needed to

make a difference, working collaboratively toward common goals.

. ?

Jillian Buriak -

Canada Research Chair in Inorganic and Nanoscale Materials,

Professor of Chemistry, University of Alberta, and Senior Research Officer, NINT

Warren Chan -

Assistant Professor, Institute of Biomaterials & Biomedical Engi-

neering, University of Toronto

David Colman -

Penfield Professor and Director, Montreal Neurological Institute

and Hospital

Michael Freund

—Canada Research Chair in Conducting Polymers and Electronic

Materials, Professor of Chemistry, University of Manitoba

Jack Gauldie -

Director, Centre for Gene Therapeutics and Professor of Pathol-

ogy and Molecular Medicine, McMaster University

Larry Goldenberg -

Director, The Prostate Centre at Vancouver General Hospital

Jed Harrison -

Professor of Chemistry, University of Alberta

Bruce Lennox -

Professor and Chair of Chemistry, McGill University

Roderick Melnik -

Canada Research Chair in Mathematical Modelling, Professor

of Mathematics, Wilfred Laurier University

Rog

Linda Pilarski -

Canada Research Chair in Biomedical Nanotechnology, Profes-

sor and Senior Scientist, Department of Oncology, Cross Cancer Institute and

University of Alberta

Peter Singer -

Director, Joint Centre for Bioethics, University of Toronto

John Steeves -

John & Penny Ryan BC Leadership Chair, Professor and Director

of ICORD

Joel Teichman -

Head of Urology, Providence Health Care

Glen Tibbits -

Canada Research Chair in Molecular Cardiac Physiology, Director

of Cardiovascular Science, BC Research Institute for Children's & Women's

Health

Dan Wayner -

Director General, Steacie Institute for Molecular Science, NRC

Chris Yip -

Canada Research Chair in Molecular Imaging, Associate Professor,

Department of Chemical Engineering and Applied Chemistry, Department of Bio-

chemistry, Institute of Biomaterials and Biomedical Engineering, University of To-

ronto

Network Manager

The Network Manager will report the Network Steering Committee. The Manager will

be responsible for all day-to-day operations and project management activities as fol-

lows:

executing all decisions made by the NANOMED CANADA Management Commit-

tee

implementation and ongoing quality control of the collaborative website

writing and uploading fresh content to the website on a weekly basis

developing and implementing a communications strategy aimed at recruiting

NANOMED CANADA members here and abroad and at communicating success

stories to the general public

coordinating workshops and weekly on-line presentations

budgeting and financial reporting

documenting and disseminating summaries of network meetings through the

NANOMED CANADA website

managing all outside contractors, including web developers, designers and writ-

ers

promoting network member research activities to the receptor community and

linking receptors with the appropriate researchers

9. ?

Appendix A - Details on the Network Steering Committee Members

Neil Branda -

Canada Research Chair in Materials Science, Director of Molecular Sys-

tems, 4D LABS, and Professor of Chemistry, Simon Fraser University - Dr. Branda will

be the Network Director of NANOMED CANADA. As winner of a 2005 NSERC Steacie

Fellowship, he has been given two years of teaching and administrative relief to focus

on collaborative research that lies at the interface of advanced materials and medicine.

This project is aligned with the goals set out in his Steacie Fellowship application. Dr.

Branda is an organic chemist with expertise in molecular switching - designing mole-

cules that change their shape and function when exposed to light, electricity or other

stimuli. This switching is important for controlling when and where diagnostics and

therapeutics can react with medical targets and for creating new advances in photody-

nami '

c therapy. Dr. Branda will also link NANOMED CANADA activities with those of 4D

LABS and other Simon Fraser University faculties.

Jillian Buriak -

Canada Research Chair in Inorganic and Nanoscale Materials, Profes-

sor of Chemistry, University of Alberta and Senior Research Officer, National Institute of

Nanotechnology (NINT) - Dr. Buriak is an inorganic materials chemist who is interna-

tionally recognized for her work in the chemistry of semiconductor surface chemistry,

and nanolithography,. and for breaking new ground in the development of new classes

of soluble metal catalysts for the organic synthesis. Her research is critical for the inte-

gration of molecular and nanoparticle materials in device applications. Dr. Buriak will

. also be able to link NANOMED CANADA activities with those of University of Alberta

and those of the National Institute of Nanotechnology (NINT) and other institutes

throughout the National Research Council of Canada (NRC) network.

Warren Chan -

Assistant Professor, Institute of Biomaterials & Biomedical Engineering,

University of Toronto - Dr. Chan is a biomedical engineeer interested in applying nano-

technology, microtechnology, molecular engineering and instrumentation design to ad-

dress biological questions that will lead to novel diagnostic schemes and therapeutic

strategies. He is internationally recognized for his research into using nanosized quan-

tum dots for tagging and tracking disease processes. He will also play a critical role in

linking NANOMED CANADA with the University of Toronto's Institute of Biomaterials

and Biomedical Engineering, which has 35 faculty members and three faculties - Ap-

plied Science and Engineering, Dentistry and Medicine.

David Colman -

Penfield Professor and Director, Montreal Neurological Institute and

Hospital - Dr. Colman is a neuroscientist who studies the interaction between cell ad-

hesion molecules. He uses in vitro and in vivo biochemical and molecular approaches

to study the myelination process and adhesion mechanisms by which intercellular junc-

tions, in particular the pre- and post-synaptic membranes in the CNS, are held to-

gether. As Director of the Montreal Neurological Institute, he will play an important role

connecting the network to the medical research community in Quebec.

Michael Freund -

Canada Research Chair in Conducting Polymers and Electronic Ma-

terials, Professor of Chemistry, Associate Professor of Chemistry, University of Mani-

/o.

toba, Manitoba Regional Materials and Surface Characterization Facility - Dr. Freund is

an analytical chemist engaged in developing a range of synthetic approaches capable

of tailoring the properties of conducting polymers for a range of applications, from

electronics to medical diagnostics. In addition, his research focuses on developing new

sensing strategies including artificial olfaction. Dr. Freund will play an active role in

linking network activities with those in Manitoba and Saskatchewan.

Jack Gauldie -

Director, Centre for Gene Therapeutics, Professor of Pathology and

Molecular Medicine, McMaster University, Fellow of the Royal Society of Canada - Dr.

Gauldie is recognized internationally for his work in defining the molecular regulation of

the acute phase inflammatory response and is a world expert in the areas of cytokine

biology and the molecular regulation of inflammation and immunity. As the Director of

McMaster University's Centre for Gene Therapeutics, Dr. Gauldie will link the activities

of NANOMED CANADA will Canada's immunology and genetics communities.

Larry Goldenberg -

Director of The Prostate Centre at Vancouver General Hospital,

Professor and Head of the Division of Urology! Surgery at University of British Colum-

bia, Research Consultant at the British Columbia Cancer Agency and Consultant

Urologist at the University of Washington - Dr. Goldenberg is a medical doctor involved

in studying diagnostics, education and novel treatment approaches of prostate cancer.

He is involved in research of MRI and 'point of care" diagnostics as well the study of

the natural biological history of prostate disease. As a clinician-scientist and Head of

the Division of Urology at University of British Columbia, Dr. Goldenberg has been in-

volved in strong translational research initiatives for many years, with his largest re-

search group studying the paradigm of advanced prostate cancer. Over the past 6

years, the Division of Urology has accumulated over $100M in peer-reviewed research

and philanthropic dollars to support its current infrastructure, research scientists,

clinician-scientists, nurses and surgeons. He will play a critical role in communicating

the issues that nanotechnology can address in cancer diagnosis and treatment, and

will link NANOMED CANADA to an international network of leading urologists, medical/

radiation oncologists and surgeon-scientists.

Jed Harrison -

Professor of Chemistry, University of Alberta, Fellow of the Royal Soci-

ety of Canada - Dr. Harrison is an analytical chemist, internationally known for his pio-

neering research into lab-on-a-chip technologies. His expertise in microfluidics will help

turn novel research into functioning devices. Dr. Harrision will also play a role in con-

necting NANOMED CANADA to other relevant faculty members at University of Alberta

and to the worldwide microfabrication community.

Bruce Lennox -

Professor of Chemistry, McGill University, Member of the Scientific

Affairs Committee, NanoQuebec and Member of the Advisory Committee , NSERC

Nano Innovation Platform (NanoIP) - Dr. Lennox is a physical organic chemist with ex-

pertise in self-assembly, who is involved in the synthesis and application of gold and

platinum nanoparticles in drug delivery and biorecognition schemes. He is also in-

volved in the development of ion-channel based electrochemical biosensors. Through

his committee positions at NanoQuebec and NanoIP, Dr. Lennox will play an important

role in linking NANOMED CANADA with some of Canada's most important nanotech-

nology networks.

Roderick Melnik -

Canada Research Chair in Mathematical Modelling, Professor of

Mathematics, Wilfrid LaurierUniversity - Dr. Melnik is a mathematician whose research

into coupled effects and the dynamics of coupled systems will lead to new mathemati-

cal and computational tools for the analysis of systems and effects. Over the recent

years, together with his collaborators in Europe and the USA, he has contributed ex-

tensively to the development of new models for studying properties of nanostructures

.His expertise will help to provide insight into the potential directions that new collabo-

rative projects may take. He will also play a role in linking NANOMED CANADA with re-

searchers in the Waterloo/Guelph region.

Linda Pilarski -

Canada Research Chair in Biomedical Nanotechnology, Professor and

Senior Scientist, Department of Oncology, Cross Cancer Institute and University of Al-

berta - Dr. Pilarski conducts translational research focused on understanding the ge-

netic events that underlie human cancer, working with clinicians to better define the

disease as it occurs in patients. Through close collaborations with engineers to de-

velop novel high throughput technology to detect and monitor cancer cells as the dis-

ease progresses, she is also facilitating the design of therapy customized to target the

vulnerabilities of each patient's malignant clone. Her experience working with ex-vivo

human cancer cells at the molecular level will be integral to the success of NANOMED

• CANADA. She is scientific director of two cross disciplinary research teams, a CIHR

New Emerging Team and the Alberta Cancer Diagnostics Consortium, dedicated to us-

ing nanoscience and microfluidics to adapt cancer diagnosis and monitoring tests to a

portable, point of care platform. She will also play an important role connecting the

network's activities to those of the medical community in Alberta.

Peter Singer -

Sun Life Financial Chair in Bioethics, Director of the University of To-

ronto Joint Centre for Bioethics, Professor of Medicine at the University of Toronto and

University Health Network, Director of the World Health Organization Collaborating

Centre for Bioethics and Director of the Canadian Program on Genomics and Global

Health at the University of Toronto - Dr. Singer's current research focus is on global

health, in particular, harnessing genomics and nanotechnology to improve health in de-

veloping countries. He will help NANOMED CANADA evaluate the ethical implications

of nanomedicine and look for opportunities to apply new technologies to global health

issues.

John Steeves -

John & Penny Ryan BC Leadership Chair, Professor and Director of

CORD, Director of the Rick Hansen Spinal Cord Injury Network, Chair of the Clinical

Trials Workshop of the International Campaign for Cures for Spinal Cord Injury Paraly-

sis - Dr. Steeves is a pioneer in creating an environment that fosters successful col-

laborative research. He founded CORD (Collaboration On Repair Discoveries) as the

first interdepartmental research group at University of British Columbia focused on

clinical and discovery research directed to spinal cord injuries. It has now evolved into

the multi-institutional ICORD (International Collaboration On Repair Discoveries), which

/2.

involves hundreds of investigators from across Canada and around the world. Dr.

Steeves has also been the President or Board Director of several Biotechnology com-

panies and remains active as a consultant on the development of novel therapeutic in-

terventions to various venture capital funds, pharmaceutical and biotech companies.

Dr. Steeves will contribute his knowledge of what it will take to cure spinal cord injuries,

and will connect NANOMED CANADA to the worldwide network of spinal cord injury

researchers.

Joel Teichman -

Head of Urology, Providence Health Care and Associate Professor of

Surgery/Urology, University of British Columbia - Dr. Teichman has internationally rec-

ognized expertise in interstitial cystitis and nephrolithiasis. He is currently developing

and will lead a transdisciplinary biophotonics program at St. Paul's Hospital. This Cen-

tre of Excellence will provide a productive and efficient intellectual environment for re-

search, development, clinical trials, and commercialization of technolOgies based on

the integration of optical devices, bio- and photochemistry, molecular engineering, mi-

cromachining and microelectronics for applications in healthcare. Dr. Teichman will play

an important role integrating the work of the biophotonics program with the activities of

NANOMED CANADA.

Glen Tibbits -

Canada Research Chair in Molecular Cardiac Physiology, Director of

Cardiovascular Science, BC Research Institute for Children's & Women's Health - Dr.

Tibbits Cardiac Membrane Research Lab investigates the cellular and molecular

mechanisms that enable the heart to adapt to environmental and pathological changes.

The research team is focusing on the factors controlling calcium ion concentrations in

cardiac muscle cells, and how these ions in turn regulate cardiac muscle contraction.

Working with the BC Institute for Children's and Women's Health, Dr. Tibbits also stud-

ies congenital heart disease, and the phylogeny of cardiac contractility regulatory

mechanisms. Dr. Tibbits has well-established connections with cardiologists and car-

diac physiologists regionally and worldwide. He will help link NANOMED CANADA to

this important group of clinical researchers.

Dan Wayner -

Director General, Steacie Institute for Molecular Science, National Re-

search Council Canada (NRC), Member NSERC Nano Innovation Platform Advisory

Board, Member, Editorial Advisory Board, Journal of the American Chemical Society,

Rutherford Medal Winner, Fellow of the Royal Society of Canada - Dr. Wayner is an or-

ganic chemist interested in surface organic chemistry of semiconductors, antibody-

antigen interactions at interfaces, DNA and protein biochip technologies, molecular/

biomolecular devices, mechanistic organic chemistry and thermochemistry and kinet-

ics of dissociative electron transfer, homolytic and heterolytic processes. As Director

General of an NRC institute, Dr. Wayner will play an important role linking NANOMED

CANADA activities to those of the vast NRC network and to those of the Government

of Canada's ad-hoc committee that is working to develop a national nanotechnology

strategy.

Chris Yip -

Canada Research Chair in Molecular Imaging, Associate Professor, De-

partment of Chemical Engineering and Applied Chemistry, Department of Biochemistry,

'/3.

Institute of Biomaterials and Biomedical Engineering, Terrence Donnelly Centre for

Cellular and Biomolecular Research, University of Toronto - Dr. Yip is a biomedical en-

gineer who is developing techniques for imaging that will make it possible to see mo-

lecular events as they are occurring. His research focus on single molecule biophysics

encompasses the development of novel approaches to correlated functional imaging of

real-time processes and dynamics on molecular length scales and computational simu-

lations of molecular self-assembly. He is particularly interested in membrane proteins

and molecular self- assembly at interfaces. His work has clear implications for under-

standing and possibly controlling processes ranging from the crystallization of biomo-

lecules and pharmaceuticals to the formation of protein complexes and the interaction

of protein and drug molecules with cellular membranes and biomimetic substrates. His

research will help the other NANOMED CANADA researchers understand the meaning

of many processes at the mOlecular scale and how they could be applied to the design

of new pharmaceutics and materials.

SRi Library - Library Course Assessments

03i0212007 02:23 PM

SIMON FRASER, UNIVERSITY

LIBRARY

Library Course Assessments

The Library participates in the course approval process for new courses at both the undergraduate and graduate levels.

By Senate motion (S.93-11) 'no new course should be approved by Senate until funding has been committed for

necessary library materials." A Library review should be conducted after new course proposals have been approved by

the department or school curriculum committee, before being considered by the Faculty curriculum committee. New

courses will not be approved at the Senate Committee on Undergraduate Studies (SCUS) or Senate Graduate Studies

Committee (SGSC) until a Library review has been completed. Even if the department states that no new library

resources are required, a report from the Library is required to confirm this view.

To submit course proposals for review by the Library, forward the following materials to Gwen Bird, Associate University

Librarian, Collections Services:

• course proposal forms

• complete course outline

• reading list created for the course, if any

• date of Faculty curriculum committee meeting (or other deadline for library report)

An assessment will be done to evaluate whether the Library's holdings and present collection development activities are

adequate to support the new course. If no new library resources are required, the course will be added to the

appropriate list below indicating the library is adequately resourced to support the course.

If additional library resources are required, a full report will be created and linked below, and the associated costs will be

identified. The costs may be one-time, to fill gaps in holdings, or ongoing, for example, to start new journal

subscriptions, or sustain book collecting in areas not now included in the Library's collection scope. If costs are

attached, the department or school is asked to transfer the required funds tothe Library's materials budget. Questions

about the process can be directed to Gwen Bird.

No Additional Library Resources Required

Unless otherwise indicated, these courses require no additional library resources based on a course location of SFU

Burnaby. In many cases, if the courses were to be offered at SFU Surrey or Vancouver or as off-campus courses,

additional Library costs might be involved. Please contact Gwen Bird for details.

Behavourial and Cognitive Neuroscience Institute (BCNI)

CIBC Centre for Corporate Governance and Risk Management

Centre for Studies in Print and Media Cultures

Centre for Imaginative Education

Centre for Studies in Wealth Management

David Wheeler Institute for Research In Mathematics Education

Nanomed Canada Research Network

BISC 357, 418, 497

http://www.lib.sfu.Ca/abOut/COIIeCtioflSICOUrseaSSeSSmefltS/lfldeX.htm ?

Page 1 of 3